Home Page : www.otcjournal.com
Email Questions or Comments To:
editor@otcjournal.com
To
OTC Journal Members:
 |
Nothing Like a Cool $200
Million |
|
You might wonder who's got the cool
$200
million, and what it has to do with today's edition of the
OTC Journal.
Remember my short term trading idea?- TapImmune (OTC BB: TPIV) I
said some positive developments would start to roll their way, and today's
post close news was the start.
The richest, or second richest man
in the world (depending on the price of Berkshire Hathaway at any one time)
is always smiling. Wouldn't you be if you could give all that money to
charity?
In 1997, Bill Gates got $200 million
poorer, but also got $200 million worth of satisfaction out of a grant
the Gates Foundation provided to The Aeras Global TB Vaccine Foundation.
On September 18, 2007, the Gates Foundation announced a five year, $200
million grant to the Aeras Foundation specifically to develop a vaccine
for TB by 2015.
As if that weren't enough, this past
week Bill Gates made another barn burner announcement related to vaccine
development. You think $200 million was a nice pile? By the Gates standards,
think again. This time it's $10 billion over the next 10 years.
Last week, on January 29th, Gates
announced his foundation would grant $10 billion to vaccine development
over the next 10 years. I guess he feels strongly about funding vaccine.
So, how does all this circle back
to today's subject- TapImmune (TPIV)? Glad you asked.
Today, post close, TPIV announced
it has signed a Letter of Intent to collaborate with the Gates favorite-
Aeras
Global TB Vaccine Foundation. The CEO of Aeras is "looking forward
to evaluating TapImmune’s adjuvant technology in our next generation genetic
vaccines.”
As I stated in my introductory presentation,
TPIV
was
going to start getting some recognition for its technology, and in the
world of vaccines this is big news.
In the meantime, TPIV started
out reasonably well for us, but rolled back down in last week's sell off.
However, since I wrote about it at $.60, it has run up to $.70,
rolled back down to $.50, and then completed the circuit to end
up back at the original entry price of $.60.
As you can see from the chart, TPIV
held up pretty nicely in the last 10 days of sell off. The uptrend remains
more or less intact. I set the SSL on this one at $.40, and we didn't even
get close. $.50 seemed to be about the bottom before it turned back up.
I continue to like this entry level
as you look at the big picture. The stock was double to triple the current
price as briefly ago as last October, and there's nothing like accumulating
at the bottom.
Also, you have tonight's post close
news, which will likely put a charge into this story for investors. Nothing
like hanging your hat near the Gates charity money if you're looking to
cure disease with vaccine developments.
Today's post close news is what I
like to refer to as a "3rd Party Endorsement" situation. None of us are
really qualified to judge the value of TPIV's TAP technology. However,
the folks at Aeres are, and they think highly enough of the therapy to
work with it.
Look for TPIV to perk up a
bit on this news.
Here's the complete text of today's
news for your review:
TapImmune Inc.
Signs R&D Collaboration Letter of Intent Agreement With Aeras Global
TB Vaccine Foundation
R&D Collaboration
Will Evaluate the Efficacy of Various TB Vaccines at Aeras Facility in
Rockville, MD
Press Release Source:
TapImmune Inc. On Monday February 1, 2010, 2:13 pm EST
BELLEVUE, Wash., Feb.
1, 2010 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV - News) announced
that it has signed a Letter of Intent (LOI) with Aeras Global TB Vaccine
Foundation to enter into an R&D collaboration effort. The overall goal
of this collaboration will be to evaluate the efficacy of TAP in concert
with novel vaccine vectors encoding TB immunogens under development at
Aeras with the aim of advancing suitable candidates to clinical development.
Aeras will conduct all pre-clinical development studies.
Aeras, one of the foremost
non-profit Product Development Partnerships, is dedicated to the development
of effective TB vaccine regimens that will prevent tuberculosis in all
age groups and will be affordable, available and adopted worldwide.
TapImmune has extensive
experience and associated intellectual property related to the use of TAP1
and TAP2 expressing vectors for the treatment of cancer and also as molecular
adjuvants for enhancing Class I presentation of vaccine immunogens.
Denis Corin, President
of TapImmune, stated, “We are proud to team with Aeras in the search for
the next generation of vaccines to eliminate the scourge of tuberculosis
from the world. We are equally proud that our technology has been recognized
as a potential meaningful contributor in that search.”
“Aeras is exploring novel
approaches to enhance the effectiveness of new TB vaccines,” said Jerald
C. Sadoff, MD, the President and Chief Executive Officer of the Aeras Global
TB Vaccine Foundation. “We are looking forward to evaluating TapImmune’s
adjuvant technology in our next generation genetic vaccines.”
About Aeras Global TB
Vaccine Foundation
The Aeras Global TB Vaccine
Foundation (www.aeras.org) is a non-profit organization working as a Product
Development Partnership to develop new tuberculosis vaccines and ensure
that they are distributed to all who need them around the world. Aeras
is funded primarily by private foundations and government aid agencies.
Aeras is based in Rockville, Maryland, where it operates a state-of-the-art
manufacturing and laboratory facility.
About TapImmune Inc.
Taplmmune Inc. is a biotechnology
company specializing in the development of innovative cell based immunotherapeutics
and vaccines in the areas of oncology and infectious disease. The
Company's lead product candidate, the AdhTAP vaccine, is designed to restore
and augment antigen presentation and subsequent recognition and killing
of cancer cells by the immune system. The Company is currently planning
the development AdhTAP for the commencement of clinical manufacturing and
toxicology studies. The Company is also developing a TAP based prophylactic
vaccine which initial tests indicate may increase the efficacy of targeted
prophylactic vaccines by up to 1000 times.
As a vaccine, the TAP
technology has the potential to significantly improve the efficacy of current
prophylactic vaccines and enhance the creation of new ones in the fight
against pandemic infectious diseases.
The TapImmune Inc. logo
is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3877.
Forward-Looking Statement
Disclaimer
This release contains
forward-looking information within the meaning of the Private Securities
Litigation Reform Act of 1995. Statements in this news release concerning
the Company’s expectations, plans, business outlook or future performance,
and any other statements concerning assumptions made or expectations as
to any future events, conditions, performance or other matters, are “forward-looking
statements”. Forward-looking statements are by their nature subject to
risks, uncertainties and other factors which could cause actual results
to differ materially from those stored in such statements. Such risks,
uncertainties and factors include, but are not limited to the risks set
forth in the Company’s most recent Form 10-K and other SEC filings which
are available through EDGAR at www.sec.gov. The Company assumes no obligation
to update the forward-looking statements.
Contact:
Taplmmune Inc.
Denis Corin, President
(866) 359-7541
Wolfe Axelrod Weinberger
Assoc. LLC
Donald C. Weinberger
Adam Lowensteiner
(212) 370-4500
Fax: (212) 370-4505 |
Home Page : www.otcjournal.com
Email Questions or Comments To:
editor@otcjournal.com
|
